Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease disproportionately affecting women.
• Cardiovascular complications, including myocardial infarction, are a major cause of morbidity and mortality in SLE patients, especially women aged 35-44.
• The precise mechanisms driving this elevated cardiovascular risk remain incompletely understood.

Purpose of the Study:

• To investigate the multifaceted factors contributing to increased cardiovascular risk in SLE patients.
• To propose a paradigm shift in cardiovascular risk assessment for SLE, considering it a coronary heart disease equivalent.
• To outline proactive management strategies for cardiovascular risk in SLE.

Main Methods:

• Review of existing literature on cardiovascular risk factors in SLE.
• Analysis of traditional cardiovascular risk factors (hypertension, diabetes) and SLE-specific factors (inflammation, antiphospholipid antibodies, corticosteroid use, renal impairment, homocysteine, early menopause).
• Proposal for a revised risk assessment and management approach.

Main Results:

• Traditional risk factors alone do not fully explain the heightened cardiovascular risk in SLE.
• SLE-specific factors such as chronic inflammation, antiphospholipid antibodies, and corticosteroid therapy likely play significant roles.
• A 50-fold increased risk of myocardial infarction is observed in women aged 35-44 with SLE.

Conclusions:

• Systemic lupus erythematosus should be considered a coronary heart disease equivalent for baseline risk assessment.
• Routine cardiovascular risk assessment and proactive management are crucial for SLE patients.
• Management should include lifestyle modifications, stringent control of blood pressure and cholesterol, and consideration of aspirin and statins.